There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sonnet BioTherapeutics Holdings (SONN – Research Report), Aravive (ARAV – Research Report) and Cyclacel Pharmaceuticals (CYCC – Research Report) with bullish sentiments.
Sonnet BioTherapeutics Holdings (SONN)
EF Hutton analyst Michael King maintained a Buy rating on Sonnet BioTherapeutics Holdings today and set a price target of $6.70. The company’s shares closed last Wednesday at $0.29, close to its 52-week low of $0.21.
According to TipRanks.com, King is a 4-star analyst with an average return of
Currently, the analyst consensus on Sonnet BioTherapeutics Holdings is a Moderate Buy with an average price target of $6.70.
See Insiders’ Hot Stocks on TipRanks >>
Aravive (ARAV)
EF Hutton analyst Anthony Butler reiterated a Buy rating on Aravive today and set a price target of $10.00. The company’s shares closed last Wednesday at $1.48.
According to TipRanks.com, Butler is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aravive with a $11.33 average price target, a 635.7% upside from current levels. In a report issued on May 11, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.
Cyclacel Pharmaceuticals (CYCC)
Oppenheimer analyst Jeff Jones maintained a Buy rating on Cyclacel Pharmaceuticals today and set a price target of $8.00. The company’s shares closed last Wednesday at $0.68, close to its 52-week low of $0.50.
According to TipRanks.com, Jones is a 3-star analyst with an average return of
Currently, the analyst consensus on Cyclacel Pharmaceuticals is a Moderate Buy with an average price target of $8.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SONN:
